Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463625 | 0.83 | DHFR (0.56) | DHFRLMNANCF1HRH3HTR3A | |
| SCHEMBL18335242 | 0.83 | DHFR (0.56) | DHFRLMNANCF1ALDH1A1HPGD | |
| SCHEMBL31106280 | 0.82 | HTR7 (0.57) | DHFRNCF1HTR1AHTR7HTR2A | |
| SCHEMBL4254231 | 0.78 | DHFR (0.46) | DHFRLMNAADORA2AADORA1 | |
| SCHEMBL4560009 | 0.77 | HRH4 (0.54) | DHFRHTR6HTR1AHTR7HTR2A | |
| SCHEMBL9167447 | 0.77 | DHFR (0.59) | DHFRHRH3 | |
| SCHEMBL13117197 | 0.77 | CYP46A1 (0.55) | NCF1HTR6HTR1AHTR7HTR2B | |
| SCHEMBL2754179 | 0.75 | HRH4 (0.49) | DHFRLMNANCF1HTR6HTR1A | |
| SCHEMBL4254224 | 0.73 | DHFR (0.51) | DHFRLMNANCF1HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL28618176 | 0.73 | DHFR (0.45) | DHFRLMNANCF1HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | DHFR 677/4885LMNA 4129/4885NCF1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.